KRASmutation in lung metastases from colorectal cancer: prognostic implications
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
KRASmutation in lung metastases from colorectal cancer: prognostic implications
Authors
Keywords
-
Journal
Cancer Medicine
Volume 5, Issue 2, Pages 256-264
Publisher
Wiley
Online
2015-12-30
DOI
10.1002/cam4.592
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Outcomes After Surgical Resection of Pulmonary Metastases From Colorectal Cancer
- (2015) Hisashi Suzuki et al. ANNALS OF THORACIC SURGERY
- KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
- (2015) S Renaud et al. BRITISH JOURNAL OF CANCER
- FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study
- (2015) Nicola Personeni et al. Clinical Colorectal Cancer
- Risk factors for survival after lung metastasectomy in colorectal cancer patients: systematic review and meta-analysis
- (2015) Michel Gonzalez et al. Future Oncology
- Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer
- (2014) V. K. Morris et al. ANNALS OF ONCOLOGY
- Association between KRAS mutation and lung metastasis in advanced colorectal cancer
- (2014) A A L Pereira et al. BRITISH JOURNAL OF CANCER
- KRASmutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases
- (2014) Nancy E. Kemeny et al. CANCER
- RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer
- (2014) Rona Yaeger et al. CANCER
- Pulmonary metastasectomy for colorectal cancer: How many nodules, how many times?
- (2014) Hong Kwan Kim WORLD JOURNAL OF GASTROENTEROLOGY
- RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases
- (2013) Jean-Nicolas Vauthey et al. ANNALS OF SURGERY
- EGFR, BRAF and KRAS Status in Patients Undergoing Pulmonary Metastasectomy from Primary Colorectal Carcinoma: A Prospective Follow-Up Study
- (2013) Thomas Schweiger et al. ANNALS OF SURGICAL ONCOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival
- (2013) Chloe E. Atreya et al. Cancer Medicine
- Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
- (2012) Mi-Jung Kim et al. BMC CANCER
- Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases
- (2012) Elena Miranda et al. CANCER
- Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations
- (2012) Ana Custodio et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Poor prognosis ofKRASorBRAFmutant colorectal liver metastasis without microsatellite instability
- (2012) Yuzo Umeda et al. Journal of Hepato-Biliary-Pancreatic Sciences
- The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer
- (2012) Francesco Sclafani et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma
- (2012) Luigi Laghi et al. PLoS One
- KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer
- (2011) J. Tie et al. CLINICAL CANCER RESEARCH
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Current treatment for colorectal liver metastases
- (2011) Evangelos P Misiakos WORLD JOURNAL OF GASTROENTEROLOGY
- PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis
- (2011) Arantza Fariña Sarasqueta et al. CELLULAR ONCOLOGY
- Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases
- (2010) L J M Mekenkamp et al. BRITISH JOURNAL OF CANCER
- Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study
- (2010) E. Mitry et al. GUT
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis
- (2009) Paloma Cejas et al. PLoS One
- Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
- (2008) Evangelia Razis et al. BMC CANCER
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started